SAN
JOSE, Calif., July 27,
2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that the
U.S. Patent and Trademark Office (USPTO) has issued a Notice of
Allowance broadening protection of Anixa's novel ovarian cancer
vaccine technology, which has been exclusively licensed from, and
is being developed in partnership with, Cleveland Clinic.
The patent is titled "Ovarian Cancer Vaccines," and covers
nucleic acid-based delivery of the vaccine. The lead inventor is
the late Dr. Vincent Tuohy of
Cleveland Clinic.
This ovarian cancer vaccine targets the extracellular domain of
anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in
the ovaries but disappears as a woman reaches and advances through
menopause. However, AMHR2-ED is expressed again in the majority of
ovarian cancers.
Dr. Amit Kumar, Chairman and CEO
of Anixa, stated, "We are pleased to receive this notice of
allowance from the USPTO, providing additional protection for our
ovarian cancer vaccine technology, including a possible mRNA
vaccine." Dr. Kumar added, "Preclinical work to advance the vaccine
is ongoing with support from the PREVENT Program at the National
Cancer Institute (NCI), which supports preclinical innovative
interventions and biomarkers for cancer prevention and
interception."
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists
of an ovarian cancer immunotherapy program that uses a novel type
of CAR-T known as chimeric endocrine receptor T-cell (CER-T)
technology, and is being developed in collaboration with Moffitt
Cancer Center. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well as a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against "retired" proteins that have been found to be
expressed in certain forms of cancer. Anixa's unique business model
of partnering with world-renowned research institutions on clinical
development allows the Company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or
follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not
historical fact may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are not statements of historical
facts, but rather reflect Anixa's current expectations concerning
future events and results. We generally use the words "believes,"
"expects," "intends," "plans," "anticipates," "likely," "will" and
similar expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-notice-of-allowance-of-additional-patent-on-ovarian-cancer-vaccine-technology-301886967.html
SOURCE Anixa Biosciences, Inc.